Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose more than 6% Kailimei® research results will be displayed on a poster at the 2026 ESMO Annual Meeting

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose more than 6%. As of press release, it had risen 5.94% to HK$16.42, with a turnover of HK$32.628,500.

^{According to the news, on July 15, according to Keji Pharmaceutical's official WeChat account, the company announced that initial positive results of clinical trials (CT041-CG4010, NCT06857786) initiated by researchers in China to consolidate treatment after adjuvant treatment after adjuvant treatment after adjuvant treatment of gastro/esophagastric junction adenocarcinoma carried out by the 2026 European Society of Oncology (CT041,)} ESMO) Annual Conference accepts poster presentations. The abstract will be published on ESMO's official website on Monday, October 19, 2026 at 00:05 Central European Daylight Time (CEST).

^{Keji Pharmaceutical said that as of July 15, since CT041-CG4010 began enrollment in May 2025, none of the participants treated with Kailimei® had recurred or metastasized gastric cancer after surgery.} Kalimei ^® is the world's first autologous CAR-T cell therapy product targeting Claudin18.2 protein for the treatment of Claudin18.2 positive solid tumors. Kailimei ^® was approved and marketed by the State Drug Administration in June 2026. It is used to treat advanced gastro/esophagastric junction adenocarcinoma (G/GEJA) that is positive for Claudin 18.2, negative for human epidermal growth factor receptor 2 (HER2), and failed at least second-line treatment. It became the first CAR-T cell treatment approved for sale in the world.